BACKGROUND: Organic anion-transporting polypeptides (OATPs) encoded by SLCO mediate the cellular uptake of many compounds, including androgens. SLCO1B3 and SLCO2B1 are polymorphic, and single-nucleotide polymorphisms of those genes alter androgen transport efficiency. We aimed to investigate the association between genetic variations in SLCOs and the progression to castration-resistant prostate cancer (CRPC). METHODS: We studied the progression to CRPC for the SLCO1B3 rs4149117 and SLCO2B1 rs12422149 genotypes in 87 prostate cancer patients who received androgen deprivation therapy (ADT). Data were analyzed using the w 2 test, Kaplan-Meier survival analysis and Cox proportional hazard model. RESULTS: SLCO3B1 genotypes were not significantly associated with the time to progression (TTP); however, patients carrying the active androgen transport SLCO2B1 genotype (GG allele) exhibited a median TTP that was 7 months shorter than that of patients with impaired androgen-transporting activity SLCO2B1 polymorphisms (GA/AA alleles) (10.0 vs 17.0 months, P ¼ 0.004). Active androgen transport genotypes of SLCO2B1 (GG allele) occurred more frequently in African and Caucasian populations than in Japanese and Han Chinese populations (Po0.001). CONCLUSIONS: These data suggest that SLCO2B1 rs12422149 variants could provide prognostic value for prostate cancer patients treated with ADT and influence ethnic differences in response to ADT. Active androgen import may be one of the underlying mechanisms of resistance to ADT, and androgen-transporting systems could provide novel biomarkers and targets for CRPC treatment.
INTRODUCTION
Androgen is required for both normal prostates and tumor development. Androgen deprivation therapy (ADT) is the mainstay of treatment for advanced prostate cancer. A majority of the advanced prostate cancers progress to castration-resistant prostate cancer (CRPC) after an initial response to ADT, and these cancers have widely variable durations of response to ADT. After progression to CRPC, treatments show limited effects, despite the development of novel agents, such as docetaxel, 1,2 abiraterone acetate, 3 cabazitaxel, 4 MDV3100, 5 radium-223, 6 and sipuleucel-T. 7 Strategies to prolong responsiveness to ADT along with effective treatments for CRPC are required to improve advanced prostate cancer prognosis. Elucidation of the mechanisms underlying castration resistance is therefore important. Several intercommunicating mechanisms regulate progression to CRPC. The androgen receptor (AR) is expressed and functional in CRPC, and the androgen-AR axis is pivotal in prostate cancer progression. 8 Several mechanisms were demonstrated to induce androgen hypersensitivity in prostate cancer cells during progression to CRPC. [9] [10] [11] Organic anion-transporting polypeptides (OATPs), which are encoded by SLCO, are a superfamily of membrane transport molecules that mediate the cellular uptake of many amphiphilic organic compounds, such as bile acids, drugs and steroid conjugates. 12 OATP1A2, OATB1B1, OAPT1B3 and OATP2B1 transport dehydroepiandrosterone sulfate (DHEAS), and OATP1B3 transports testosterone. [12] [13] [14] Thus, OATPs mediating androgen transport may be involved in prostate cancer susceptibility and progression.
OATP1B3 and OATP2B1 are the most appropriate candidates of several OATPs for investigating the association with prostate cancer because these OATPs are expressed in the prostate, 15, 16 and the androgen transport activities of the functional genotypes of SLCO1B3 and SLCO2B1, which encode OATP1B3 and OATP2B1, respectively, have been well characterized.
several polymorphic variants; of them, the SLCO2B1 G allele (GG) at rs12422149 (935G4A, Arg312Gln) exhibits higher DHEAStransporting activity than is exhibited by the A alleles (GA/AA). Augmented DHEAS uptake by active transporting genotype induced AR activation and increased cell proliferation of androgen-sensitive prostate cancer cells.
14 Functional genetic variants of SLCO1B3 and SLCO2B1 may influence prostate cancer susceptibility, progression and castration resistance by altering intracellular androgen levels. A few studies in Caucasians indicated an association between single-nucleotide polymorphisms (SNPs) in SLCO1B3 and prostate cancer progression, but the results were inconsistent. 13, 14, 17 Only one study regarding the influence of the SLCO2B1 genotype on prostate cancer progression was published in the English literature. 14 Ethnic differences in response to ADT were suggested, 18, 19 and the genotype frequencies of SLCO1B3 and SLCO2B1 are different among ethnic populations. 14, 16, [20] [21] [22] [23] [24] [25] Thus, different genotype frequencies of SLCOs may affect ethnic differences in response to ADT.
In this study, we assessed the association between functional SLCO1B3 and SLCO2B1 SNPs and prostate cancer progression during ADT in a Japanese population. In addition, we compared polymorphisms of these genes between Japanese and other ethnic populations to understand whether genetic variation underlies the ethnic differences in response to ADT.
MATERIALS AND METHODS

Study population and DNA samples
We used DNA samples that were collected from 532 Japanese men who presented at our hospital between June 1993 and July 1995 and between March 1996 and December 2002, as described previously. [26] [27] [28] The association between SLCO genotypes and prostate cancer progression was investigated in 87 consecutive histologically diagnosed prostate cancer patients who received ADT between March 1996 and December 2002. All subjects signed a written informed consent, and this study was reviewed and approved by the Ethics Committee of Medicine and Medical Care, University of Occupational and Environmental Health, Japan.
Genotyping
We analyzed SNPs at rs4149117 and rs12422149 in SLCO1B3 and SLCO2B1, respectively, because in vitro studies demonstrated that these SNPs altered androgen transport efficiency. 13, 14 Germline DNA was isolated from peripheral blood cells. PCR amplification was performed using Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA, USA). The primers, annealing temperature (Tm) and cycle numbers were as follows: SLCO1B3: 
Prostate cancer outcome
Time to progression (TTP) was defined as the duration from ADT initiation to the date of progression to CRPC. CRPC was defined according to the definition in the European Association of Urology guidelines. 29 Briefly, these criteria included castration serum levels of testosterone, three consecutive increments in PSA resulting in two 50% increases over the nadir despite consecutive ADT, antiandrogen withdrawal for at least 4 weeks for flutamide and for at least 6 weeks for bicalutamide, progression or appearance of 42 lesions on a bone scan and soft tissue lesions. Overall survival (OS) was calculated from the ADT initiation to death or the last follow-up day.
Statistical analysis TTP and OS were calculated using the Kaplan-Meier method, and the significance of the difference was calculated using the generalized Wilcoxon test. The Cox proportional hazard model was used to estimate the hazard ratio with an adjustment for covariates, including the SLCO genotypes and clinical factors that might affect the outcome of ADT. 30 The clinical factors included in the model were the stage (M0, M1), PSA value at ADT initiation (higher, lower than median), Gleason score (p7 and X8), antiandrogen (yes, no) and treatment before ADT (yes, no). Differences in genotype frequencies between ethnic groups were analyzed with the w 2 test. Po0.05 was considered significant.
RESULTS
Because of postulated polymorphism function, genotypes were analyzed using the dominant effects model (SLCO1B3 rs4149117 TT/TG versus GG; SLCO2B1 rs12422149 GG versus GA/AA). The SLCO1B3 TT/TG alleles were associated with shorter TTP during ADT, but this difference was of borderline significance (median TTP 11.5 vs 17 months, P ¼ 0.087; Figure 1a) . The TTP in men with the SLCO2B1 GG allele was significantly shorter than for those with the GA/AA alleles (10.0 vs 17.0 months, P ¼ 0.004, Figure 1b) .
Multivariate survival analysis was also performed using the Cox proportional hazard model. The variables included in the model were SLCO genotypes and clinical factors that might affect the progression during ADT. 30 Adjustment for these clinical indicators did not alter the result materially, and a significant association between the SLCO2B1 genotypes and the TTP during ADT was still observed (P ¼ 0.028, Table 2 ).
The OS was unaffected by the SLCO2B1 rs12422149 or SLCO1B3 rs4149117 variants (P ¼ 0.925 for SLCO2B1 and P ¼ 0.821 for SLCO1B3).
We examined the genotypes of SLCO2B1 rs12422149 in 532 Japanese men. These subjects included 152 prostate cancer patients, 177 urothelial cancer patients, 99 noncancer patients and 104 healthy men. The genotype frequencies of SLCO2B1 rs12422149 in different ethnic groups were compared using our cohort and published data 14, 16, [23] [24] [25] (Table 3 ). In Caucasians, 58.6% were prostate cancer patients 14, 16, 23, 24 and disease distribution in Africans and Han Chinese were unknown. 23 In the previous studies in Japanese, 51.1% were patients with pulmonary hypertension 25 and others were unknown.
23 SLCO2B1 rs12422149 genotype frequencies in our cohort were almost identical among different disease groups.
The SLCO2B1 rs12422149 GG and GA/AA frequencies were 41.8% (260/622) and 58.2% (362/622) in Japanese and 49.3% (34/ 69) and 50.7% (35/69) in Han Chinese subjects, respectively, but 86.4% (114/132) and 13.6% (18/132) in Africans and 80.0% (1324/ 1655) and 20.0% (331/1655) in Caucasians, respectively. The allelic frequencies of SLCO2B1 in the Japanese were similar to those in the Han Chinese but significantly different from those in the African and Caucasian populations (Po0.001). The active transporting genotype of SLCO2B1 rs12422149 (GG allele) was more frequent in African and Caucasian populations than in Asians. These findings suggest that differences in the genotype frequencies of SLCO2B1 rs12422149 may influence the racial difference in response to ADT.
DISCUSSION
Accumulated data suggest that many pathways are involved in the progression of androgen-sensitive prostate cancer to CRPC and that AR signaling is a key to these processes. Proposed ARrelated mechanisms of castration resistance are as follows: AR overexpression 9, 31 AR mutation, variation, gain of function or impaired ligand specificity [32] [33] [34] Cofactor expression alteration 10, 35 Adrenal and intratumoral androgen synthesis. In addition, androgen influx into cancer cells may contribute to the acquisition of castration resistance. Prostate cancer cells incorporate androgen by passive diffusion and active transport. Without ADT, enough androgen exists around prostate cancer cells, and sufficient intracellular androgen may be obtained by passive diffusion. Conversely, during ADT, the extracellular androgen concentration is extremely low, and the androgen influx by passive diffusion should be limited. In this situation, active transport may significantly affect intracellular androgen levels.
Testosterone is an OATP1B3 substrate, and DHEAS is a substrate of OATP1B3 and OATP2B1. [12] [13] [14] DHEA is converted to testosterone; furthermore, DHEA can directly bind and activate AR.
14 Thus, both testosterone and DHEA are directly and indirectly involved in prostate cancer progression. OATP1B3 and OATP2B1 are expressed in many tissues. Pressler et al. 15 showed elevated SLCO1B3 mRNA expression in prostate cancer tissue compared with that in normal prostate tissue. Wright et al. 16 demonstrated that SLCO2B1 mRNA expression was higher in CRPC metastases than in normal or untreated prostate cancer tissue. These observations suggest that OATPs/SLCO may be involved in progression to CRPC. Investigating androgen transport may provide insight into the mechanisms underlying the castration resistance of prostate cancer.
Previous studies showed that SNPs at SLCO1B3 rs4149117 affected the progression during ADT and the OS after prostate cancer diagnosis.
13,17 However, we and Yang et al. 14 did not observe an association between the SLCO1B3 genotype and either progression during ADT or OS. This inconsistency may have resulted from the differing sample size, patient characteristics and definition of progression. The definition of CRPC is important for assessing the efficacy of ADT because different definitions have considerably different results; in previous reports, the definitions of CRPC were unclear. For example, Sharifi et al. 17 defined androgen independence as the first increase in PSA, an unconventional definition. In the present study, we used the clinically accepted definition of CRPC 29 to assess progression during ADT. In the study that suggested an association between the SLCO1B3 genotype and the OS, 13 patients with CRPC were enrolled in clinical trials that tested several therapeutic agents. Thus, the OS in that study might also be influenced by treatments other than ADT.
Our results revealed that the SLCO2B1 rs12422149 genotype influenced TTP during ADT: patients with the impaired androgen transport genotypes SLCO2B1 rs12422149 GA/AA exhibited longer TTP. Yang et al.
14 also demonstrated a significant difference in TTP during ADT with SNPs at this site of SLCO2B1. Although several clinical factors, such as PSA level, clinical stage and Gleason score, have a great impact on progression to CRPC, 30 multivariate analyses in our cohort indicated that the SLCO2B1 rs12422149 genotype was an independent factor influencing TTP and may be a powerful biomarker for predicting the progression of prostate cancer during ADT. In spite of significant difference in TTP, SLCO2B1 rs12422149 variants did not affect OS. Not only the response to ADT but also the response to CRPC treatments should determine OS. Our subjects received various treatments after progression to CRPC such as estrogens, cytotoxic chemotherapy or palliative radiation. Different treatments for CRPC may be one of the reasons why OS was unaffected by SLCO2B1 rs12422149.
Japanese patients experience better cause-specific and overall survival after ADT initiation than is experienced by Caucasians. At 60 months after ADT initiation, the OS was 65.5% in Japanese and 41.7% in Caucasian patients (P ¼ 0.01). The cause-specific survival was also better in Japanese than in Caucasian patients (P ¼ 0.036). 18 The effect of ADT on the racial differences for survival was also analyzed in a large cohort of patients (n ¼ 64 475) with locoregional prostate cancer who received ADT. 19 In that cohort, the survival of Asians and Hispanics was better than that of Caucasians or African Americans, whereas no significant difference was observed between Caucasians and African Americans. Asians had the best survival and a 37% decreased risk of dying compared with that of Caucasians after adjustment for prognostic factors, such as tumor characteristics, treatments and sociodemographics (Po0.001). The underlying mechanisms of these ethnic differences are not well understood. In the present study, the active androgen transport SLCO2B1 rs12422149 genotype (GG) was less frequent, whereas impaired androgen transport genotypes (GA/AA) were more frequent in Japanese and Han Chinese populations than in Caucasians and Africans. The different frequencies of the functional SLCO2B1 rs12422149 genotype in different ethnic populations may partially explain the ethnic disparities in response to ADT.
Our study had some limitations. The sample size was relatively small, and the results were from an exclusively Japanese population. A majority of our subjects were old and had advanced stages, and ADT was performed as primary therapy in most subjects. Analyses using a larger sample size and including other ethnic groups and patients with diverse clinical characteristics may validate our results. Intracellular androgen levels are determined by the balance of androgen influx and efflux; therefore, both influx and efflux mechanisms may be involved in intracellular androgen levels. However, candidate molecules mediating active androgen efflux from cells are, to date, unidentified. Further studies are required to elucidate those issues.
In conclusion, the SLCO2B1 rs12422149 variants may determine the TTP during ADT by altering androgen transporting activity and may influence the racial differences in response to ADT. Androgen-transporting genes may be involved in the resistance to ADT and may help elucidate the biological basis of CRPC. Androgen-transporting systems could provide novel biomarkers and targets for CRPC treatment, and OATP inhibitors may prolong the time to CRPC.
